on the HUNT for the Next DIAMOND in the ROUGH
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks Den for updating the IBOX I started it last week but never completing it with personal issues this past week.
Its good to back home....and to see this board more active. Company has done well this past week- Now lets make some $$$
Happy to have you onboard
Once we clear .01 then some larger bocks will be bought and we really move
IMO I don't think we will see that- I believe we will see a buyout for 30 mil. plus before that happens. One day the shareholders will see their accounts increase 1000-2000% depending on what they are holding. I could be wrong about the buyout but not about the $
I wouldn't want to be caught with my pockets empty when the BIG news of what they are working on comes out
http://www.jsbarkats.com/
Wow ....this law firm has 5 different locations around the world.
Prior to founding the JSBarkats PLLC law firm Mr. Barkats built the Securities & Capital Markets group at an old mid-sized Manhattan firm. Mr. Barkats practiced with leaders in the alternative public offering (APO) and PIPEs community, such as at the international law firm of Haynes & Boone, LLP in New York, and the leading PIPE firm of Sichenzia Ross Friedman and Ference, LLP, where he experienced the current evolution of the industry and its ramifications for issuers. Because of his experience working with various clients across many major sectors and access to institutional relationships, Mr. Barkats is uniquely positioned to provide expert advice and insight to help companies attract and retain capital while complying with SEC requirements.
Sunny Joseph Barkats, Esq., Partner
His principal experience has been in private placements, mergers, acquisitions and dispositions, SEC compliance, public offerings, general 1933 and 1934 Act matters and strategic business relationships. He also represents issuers, underwriters, placement agents and others as well as lenders and financial participants, in mergers and acquisitions, IPOs, private equity, private placements and PIPE transactions. Mr. Barkats’ core practice focuses on the representation of small and mid-sized companies, particularly in the internet, defense, biotechnology, and “green” technology industries
I am Grateful to be an investor in this Co. that will save Many lives. I just received bad news this morning that my grandfather died He was 93 but did not suffer. Hopefully this will be a good day $ wise with many more to come. This Company is the Future of Biotechs
Amarantus BioSciences Retains JS Barkats in New York as Corporate & Securities Counsel
Date : 10/15/2012 @ 8:17AM
Source : PR Newswire
Stock : Amarantus Biosci (AMBS)
Quote : 0.0062 0.0 (0.00%) @ 5:32AM
Amarantus BioSciences Retains JS Barkats in New York as Corporate & Securities Counsel
Amarantus BioSciences, Inc. (OTCQB: AMBS), today announced that it has retained the legal services of JS Barkats, PLLC ("JS Barkats") to represent the Company as its corporate and securities counsel. Going forward, JSBarkats will represent the Company on all corporate, securities, capital markets, divestitures, partnerships, sponsorships and regulatory compliance matters. Amarantus will continue to work with Wilson, Sonsini, Goodrich & Rosati, LLP for all MANF intellectual property matters, and with Foley & Lardner, LLP on all diagnostic intellectual property matters.
"We are excited to represent Amarantus and be given the opportunity to bring value-added services to the table for our new client. Our team of experienced attorneys is impressed with the Company's proprietary technology and approach to treating Parkinson's disease and Traumatic Brain Injury," said Sunny Joseph Barkats, Founding Partner at JS Barkats. "Amarantus' corporate awareness programs, through its #C4CT concussion program and emerging relationships with professional athletes, are pioneering within development-stage biotechnology that will allow the Company to carve out a unique position for itself in the marketplace as it executes on its business strategy."
Robert Rash, the co-managing partner of the Firm in the Alabama offices added "As a CPA and a securities attorney, I am very interested in Amarantus revenue model being prosecuted through the aggregation and partnering of the Parkinson's NuroPro blood test and Alzheimer's LymPro blood test. JSBarkats believes this Company has extremely bright, talented people on its management team and the business approach is unique and innovative. Hence, we are delighted to represent Amarantus in order to assist management in maximizing the Company's value for shareholders."
About JSBarkats, PLLC:
JS Barkats, a boutique law firm headquartered in the heart of midtown-Manhattan in New York, has an experienced team of 22 attorneys with satellite offices in Alabama, Florida and Israel, as well as international affiliated offices. The firm specializes in, IPO's, APO's for public companies, SEC compliance and representation, intellectual property, licensing, corporate partnerships, tax law, commercial and securities litigation, entertainment and brand awareness. www.JSBarkats.com
About Amarantus BioSciences, Inc.:
Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. Taken together, the Company is pursuing market opportunities that could potentially represent $1B+ in annual revenues. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. For further information please visit www.Amarantus.com.
$AMBS was .30last year and is now in better positionthan last @ .0062 now...has been floating under the radar
Major Run coming and significant News on the Horizon IMO
Don't get caught chasing it....load up now
The instant revenue from the Parkinson test with a cost of $350 per test and a 70 to 80% markup. Company Ceo making all the right moves
$AMBS This could very well go to 10 cents plus....market cap of 600k now -should be over 10 mil. with patent for MANF in USA alone....and they have many other significant patents in Europe
$AMBS 25-1 Forward Split LAST YEAR
Amarantus BioSciences Announces Completion of Capital Restructuring
http://ih.advfn.com/p.php?pid=nmona&article=48061536
$AMBS Amarantus BioSciences Awarded US Patent Protecting Composition of Matter for MANF
HERE is the Patent- is there something I'm missing?
http://ih.advfn.com/p.php?pid=nmona&article=50705390
$AMBS Wow $3000.00 for 1 mg. of MANF
Maybe someone can help me out with this one
Why are these Companies selling it?
Does Amarantus know about this?
http://www.peprotech.com/en-US/Pages/Product/Recombinant-Proteins/Neurotrophins/Recombinant_Human_MANF/450-06
$AMBS and this one too.....do they only own in U.S.
In a PR they stated worldwide
http://www.sinobiological.com/MANF-Protein-g-3731.html
$AMBS If they own worldwide rights ....why is this Co. Selling it?
http://www.rndsystems.com/product_results.aspx?m=3285
$AMBS Mesencephalic astrocyte-derived neurotrophic factor (MANF) protects the heart from Ischemic damage and is selectively secreted upon ER calcium depletion
http://www.jbc.org/content/early/2012/05/29/jbc.M112.356345
Parkinsons is just the tip of the iceberg MANF has been shown to help with many other neurogical disorders as well. The key is the test to find early detection of these killers. Amarantus already has one for parkinsons and now onto Alzheimer's. With just these two alone...the market is HUGE If you do a little DD on MANF you will be amazed.
I feel grateful to be an investor in this Breakthrough Technologyand Amarantus owns Worldwide rights to this compound which repairs cells that are dying when you have these conditions
I sold way too early on this one...entered at .24 ...exit .29 but looking to re-enter
Any profit is good profit.
I'm in another bio and its just coming out of research phase and into developmental
Very Very undervalued
What will a Tsa approval mean in revenues for the last quarter...any guesses?
Is there news expected on Monday or just people getting impatient and moving on to the next play?
$AMBS Here's the link
http://www.biomedreports.com/2009111818487/ready-to-run-power3-medical-products-otcpwrm.html
On September 16 2009, Vermillion, Inc. (OTC:VRMLQ), the anguished little company seeking Chapter 11 bankruptcy protection, received clearance for it's ovarian cancer diagnostic test from the US Food and Drug Administration. That morning, shares in the company went from pennies to a dollar on the news.
I truly believe this may be much bigger than this in the long run...I would like to accumulate more but I think 1.5 million will do for now.
For anyone interested in this Co. I would look much deeper than just the charts- take some time and watch a few videos and read up on the articles.
I know much of it is hard to understand but this company owns the rights to a molecular protein compound which has been researched by independent labs for the last 7 years with a breakthrough on the horizon. i just hope they don't sell out before I'm able to swing this a few times. The patents alone could be worth 50 to 100 million and this co. has a market cap. of 600k.....don't miss this one- it will be the most posted board in the near future.
Everyone have a Great Weekend.
Here is the link to the video explaining the revenue stream selling to other companies before FDA approval....its about 20 minutes long
http://www.onemedplace.com/database/list/cid/13336
the blood test (nuropro) for early detection of Parkinson's is going to generate $350 per test. I have to find the video where Gerald goes thru the projected #'s I believe he said it would generate about 30 million but i could be wrong...that would be for 85,000 tests.
I have a feeling next week is going to be Fun....
Rushed home to catch the last 20 min. ...looking strong
Frustrating but Patience will pay off.....at the very least ....the company is getting put on the radar and when it starts to rise we will have many more on board for the ride to come.
Amarantus BioSciences Acquires Option to License LymPro Alzheimer's Diagnostic Blood Test
PR Newswire
SUNNYVALE, Calif., Oct. 11, 2012
SUNNYVALE, Calif., Oct. 11, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centred on its proprietary anti-apoptotis therapeutic protein MANF
, today announced that it has acquired an exclusive option to license the LymPro Alzheimer's Diagnostic Blood Test from Memory Dx, LLC (MDx), formerly known as Provista Life Sciences, LLC. Under the terms of the agreement, Amarantus agreed to pay 500,000 restricted shares of its common stock to MDx for exclusive negotiating rights through December 31st, 2012 to the LymPro blood test.
"Coming off our recent success in securing the license for the NuroPro Parkinson's Diagnostic Blood Test, the LymPro Alzheimer's Diagnostic Blood Test option agreement will give Amarantus additional leverage over the next few months in negotiations as we look to partner our diagnostic assets," said Gerald E. Commissiong, President & CEO of Amarantus. "The market opportunity for a minimally-invasive Alzheimer's blood test capable of detecting the disease early on is tremendous given recent Phase III clinical data produced by Pfizer, Johnson & Johnson and Eli Lilly all suggesting that patients with mild cases of Alzheimer's disease are the best sub-population of clinical candidates for beta-amyloid targeting disease-modifying treatments, a potential blockbuster target for each of these companies. We expect that NuroPro and LymPro will create a compelling investment package for potential partners."
The LymPro Alzheimer's diagnostic blood test works by identifying immune-based biomarkers in the blood of Alzheimer's patients. It allows physicians to differentiate Alzheimer's disease from other forms of dementia based upon these biomarkers; potentially making it an invaluable tool in patient recruitment for Alzheimer's disease therapeutic clinical trials where there has been a well-documented history of patient recruitment miscues.
LymPro originates with the University of Leipzig in Germany and has been funded primarily through private investors and research grants from the National Institutes of Health ("NIH"). LymPro has completed two human clinical studies to date, and is set to move immediately into the Phase 2 validation study required to begin generating revenue as a laboratory developed test ("LDT") at an already-selected Certified Laboratory Improvement Amendments ("CLIA") certified laboratory. Thereafter, we anticipate LymPro will begin its regulatory process with the Food and Drug Administration towards approval.
About Amarantus BioSciences, Inc.
Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. For further information please visit www.Amarantus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.
MEDIA CONTACTSAmarantus BioSciences, Inc.Gerald E. Commissiong408-737-2734pr@amarantus.com
SOURCE Amarantus BioSciences, Inc.
I could see us easily reach a penny + this week with the right investors
We just need to establish an uptrend first. This will be a long time play for me and I'm sure within a month or less be riding free shares with selling into the pops and buying on the dips- just a bit stressful- don't want to chance being out while they are bought out
Let's have a Great Day!
Advancing MANF as a disease-modifying treatment for Parkinson’s disease continues to be our primary focus. We anticipate announcing interim results from on-going delivery experiments by the end of October. The Company is working to secure funding to advance MANF towards an Investigational New Drug filing for Parkinson’s disease with the Food and Drug Administration.
From a January PR and they have chosen Amarantus after 10 months of searching.....They must see the BIG picture and the Breakthrough Amarantus has discovered and now is going to develop
RBCC Seeks Out the Next Big Bioscience Breakthrough
Print
Alert
Rainbow Coral Corp (OTCBB:RBCC)
Historical Stock Chart
1 Year : From Oct 2011 to ChartsOct 2012
Click Here for more Rainbow Coral Corp .
Rainbow BioSciences, a division of Rainbow Coral Corp. (OTCBB: RBCC), is staying connected in the center of advanced bio-research in Houston.
To spearhead these efforts, RBCC attended a breakfast forum, hosted by BioHouston--one of the nation’s preeminent drivers of life sciences research and commercialization. Events such as these enable the Company to meet with the potential developers of the next breakthrough in bioscience research and get involved at the ground level.
RBCC works with early stage biotech entities that may hold the key to the next big advances in bioscience discoveries. Companies such as Advanced Cell Technology, Inc. are developing cellular therapies for the treatment of diseases and conditions that impact tens of millions of people worldwide. Connecting with forward-thinking and innovative leaders like Advanced Cell Technology could help RBCC develop and market the next big breakthrough in the industry.
Houston, TX is a recognized as an incubation hub for bioscience research and technology and is home to the world’s largest medical complex. RBCC will continue to attend Houston-based events to further solidify its place as a source for leading-edge bioscience initiatives.
For more information on Rainbow BioSciences, Rainbow Coral’s biotech division, please visit www.rainbowbiosciences.com/investors.
Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Amgen Inc. (NASDAQ: AMGN), Biogen Idec, Inc. (NASDAQ: BIIB), Gilead Sciences, Inc. (NASDAQ: GILD) and Life Technologies Corporation (NASDAQ: LIFE).
$AMBS American Bulls ....BUY CONFIRMED
http://www.americanbulls.com/StockPage.asp?CompanyTicker=AMBS&MarketTicker=OTC&TYP=S
$AMBS I'm feelin another run to 2 cents plus this week :)
30 million has already been spent on research over the years.....and they have numerous patented formulas which have been reviewed as previous PR's have stated ....they are 3/4 of the way through the woods and you are lost.
Any financing needed will be announced shortly to finish the last sprint through the woods.
There are too many organizations they are partnering with to ever have a problem with financing.
But keep up the good work....you are doing your best and that's all we can ask for- lol
Everything is falling into place
“The fundamental progress the Company has made since our First Annual CEO Letter was released in May has been quite significant. We have achieved the following milestones:
1. Positive animal proof-of concept data for MANF in the multi-billion dollar Myocardial Infarction market;
Acute Myocardial Infarction
Approximately 800,000 events of acute myocardial infarction occur in the US each year and, despite all of the advances in medicine and intervention, about 20% or approximately 160,000 patients have a ST-Elevation MI (STEMI) resulting in a reduced Left Ventricular Ejection Fraction (LVEF) of less than 50%. That means that their MI was big enough and their heart so damaged that the remaining heart muscle could not compensate for the damaged heart tissues and, over time, the hearts starts to fail. These patients are at significant risk of downstream adverse events including congestive heart failure, re-current MI, significant arrhythmias, premature death or acute coronary syndrome
2. Secured the license for the NuroPro Parkinson’s diagnostic blood test; and
3. Successfully concluded our research collaboration with Banyan Biomarkers, showing positive proof-of concept data for MANF in Traumatic Brain Injury
Banyan Biomarkers, Inc. Awarded $26.3 Million Department of Defense Contract for Diagnostic Test for Traumatic Brain Injury
http://www.businesswire.com/news/home/20101005005193/en/Banyan-Biomarkers-Awarded-26.3-Million-Department-Defense
Keep up the good work.TY
I'm loading more